

AMENDMENTS TO THE CLAIMS

1. (**Currently Amended**) A method of evaluating [[drug]] sensitivity of an individual human subject to a drug, which comprises:

linking a gene polymorphism to individual drug sensitivity, the gene polymorphism being haplotype to individual drug sensitivity, the haplotype being estimated from gene polymorphisms that are linkage disequilibrium determined by selecting:

at least two nucleotide sequence groups selected from the group consisting of:

IVS3 + A6151G of SEQ ID NO: 28;

IVS3+A8449G of SEQ ID NO: 29, TAA+G886A of SEQ ID NO: 33, TAA+T1360C of SEQ ID NO: 34, TAA+T1371C of SEQ ID NO: 35, TAA+G1670A of SEQ ID NO: 36, TAA+G1709A of SEQ ID NO: 37, TAA+C2008T of SEQ ID NO: 38, TAA+A2109G of SEQ ID NO: 39, TAA+A2274G of SEQ ID NO: 40, TAA+G2287A of SEQ ID NO: 41, TAA+G2395C of SEQ ID NO: 42, TAA+G2458C of SEQ ID NO: 43, TAA+T2482C of SEQ ID NO: 44, TAA+G2497A of SEQ ID NO: 45, TAA+G2656T of SEQ ID NO: 46, TAA+C2714A of SEQ ID NO: 47, TAA+G2820T of SEQ ID NO: 48, TAA+G2907T of SEQ ID NO: 49, TAA+T3423C of SEQ ID NO: 50, TAA+A4026G of SEQ ID NO: 51, TAA+4585(A)_n of SEQ ID NO: 52, TAA+A4861C of SEQ ID NO: 53, TAA+A5359G of SEQ ID NO: 54, TAA+A6074C of SEQ ID NO: 55, TAA+T6866G of SEQ ID NO: 56, TAA+C6922G of SEQ ID NO: 57, TAA+7075del(322bp) of SEQ ID NO: 58, TAA+C7427T of SEQ ID NO: 59, TAA+7483del(A) of SEQ ID NO: 60, TAA+T7536C of SEQ ID NO: 61, TAA+A7589G of SEQ ID NO: 62, TAA+C8116T of SEQ ID NO: 63, TAA+C8165T of SEQ ID NO: 64, TAA+G8281A of SEQ ID NO: 65, TAA+8386(A)_n of SEQ ID NO: 66, TAA+C9000T of SEQ ID NO: 67, TAA+A9564G of SEQ ID NO: 68, TAA+G9669A of SEQ ID NO: 69, TAA+T9716A of SEQ ID NO: 70, TAA+T9839G of SEQ ID NO: 71, TAA+C9994A of SEQ ID NO: 72, TAA+C10083A of SEQ ID NO: 73, TAA+10223(A)_n of SEQ ID NO: 74, TAA+A10247T of SEQ ID NO: 75, TAA+A10535G of SEQ ID NO: 76, TAA+G10704A of SEQ ID NO: 77, TAA+T10752G of SEQ ID NO: 78, TAA+C11100T of SEQ ID NO: 79,

TAA+C11129A of SEQ ID NO:80, TAA+11132(CA)_n of SEQ ID NO: 81, TAA+A11133G of SEQ ID NO: 82, TAA+11368del(TCTC) of SEQ ID NO: 83, TAA+T11411C of SEQ ID NO: 84, TAA+T11431C of SEQ ID NO: 85, TAA+11449ins(TTTC) of SEQ ID NO: 86, TAA+G11541A of SEQ ID NO: 87, TAA+A11602C of SEQ ID NO: 88, TAA+C11650T of SEQ ID NO: 89, TAA+C11918T of SEQ ID NO: 90, TAA+A11956C of SEQ ID NO: 91, TAA+A12143G of SEQ ID NO: 92, TAA+A12630G of SEQ ID NO: 93, TAA+T12681C of SEQ ID NO: 94, TAA+T12831C of SEQ ID NO: 95, TAA+G12834C of SEQ ID NO: 96, TAA+13236(T)_n of SEQ ID NO: 97, TAA+T13971G of SEQ ID NO: 98 and TAA+G2025A of SEQ ID NO: 100,

wherein said gene polymorphisms are in linkage disequilibrium with IVS3 + A6151G of SEQ ID NO: 28;

the drug being at least one member selected from the group consisting of methamphetamine, methylenedioxymethamphetamine, amphetamine, dextroamphetamine, dopamine, morphine, DAMGO, codeine, methadone, carfentanil, fentanyl, heroin, cocaine, naloxone, naltrexone, nalorphine, levallorphan, pentazocine, buprenorphine, oxycodone, hydrocodone, levorphanol, etorphine, dihydroetorphine, hydromorphone, oxymorphone, ethanol, methanol, diethyl ether and tramadol

~~the nucleotide sequences SEQ ID NOS: 1 to 15;~~

~~a nucleotide sequence group consisting of the nucleotide sequences of SEQ ID NOS: 16 and 25,~~

~~a nucleotide sequence group consisting of the nucleotide sequences of SEQ ID NOS: 26 and 27, and~~

~~a nucleotide sequence group consisting of the nucleotide sequences of SEQ ID NOS: 28-98, and~~

~~selecting at least one nucleotide sequence from each of the selected at least two nucleotide sequence groups.~~

2-21. (Canceled)

22. (New) The method according to claim 1, wherein the gene polymorphisms in linkage disequilibrium with IVS3+A6151G of SEQ ID NO: 28 are IVS3+A8449G of SEQ ID NO: 29, TAA+A2109G of SEQ ID NO: 39 and TAA+G2287A of SEQ ID NO: 41.

23. (New) The method according to claim 22, wherein the gene polymorphism that is in linkage disequilibrium with IVS3+A6151G of SEQ ID NO: 28 is IVS3+A8449G of SEQ ID NO: 29.

24. (New) The method according to claim 1, wherein the drug is selected from the group consisting of methamphetamine and fentanyl.

25. (New) The method according to claim 22, wherein the drug is selected from the group consisting of methamphetamine and fentanyl.

26. (New) The method according to claim 23, wherein the drug is selected from the group consisting of methamphetamine and fentanyl.

27. (New) The method according to claim 1, wherein the drug is methamphetamine.

28. (New) The method according to claim 22, wherein the drug is methamphetamine.